Genyzme files BLA

GENZ submitted a BLA to the FDA for marketing approval of Fabrazyme agalsidase beta enzyme replacement therapy to treat Fabry disease. On June 16, Transkaryotic (TKTX) submitted a BLA to the FDA for i...